Cargando…
Pulmonary squamous cell carcinoma and sorafenib
KEY CLINICAL MESSAGE: Pulmonary squamous cell carcinomas are not often thought to sensitive to targeted agents, like their cousin the adenocarcinoma of the lung. With appropriate testing of molecular markers, squamous cell carcinomas, like adenocarcinomas of the lung, melanomas, and renal cell carci...
Autores principales: | Gollard, Russell, Garcia, Diana, Natale, Ron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302627/ https://www.ncbi.nlm.nih.gov/pubmed/25614813 http://dx.doi.org/10.1002/ccr3.95 |
Ejemplares similares
-
Splenic non-Hodgkin’s lymphoma without organomegaly: occult presentation with fatal course and post-mortem diagnosis
por: Gollard, Russell P, et al.
Publicado: (2010) -
Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report
por: Gollard, Russell, et al.
Publicado: (2023) -
Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021) -
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021) -
Multiple Pulmonary Metastases of Cutaneous Squamous Cell Carcinoma
por: Kushima, Hisako, et al.
Publicado: (2018)